<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="63030">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02285361</url>
  </required_header>
  <id_info>
    <org_study_id>1200.235</org_study_id>
    <nct_id>NCT02285361</nct_id>
  </id_info>
  <brief_title>GIOTRIF rPMS in Korean Patients With NSCLC</brief_title>
  <official_title>A Regulatory Requirement Post-marketing Surveillance Study to Monitor the Safety and Efficacy of GIOTRIF®(Afatinib Dimaleate, 20mg, 30mg, 40mg, q.d) in Korean Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Mutation(s)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      To monitor the safety profile and efficacy of GIOTRIF®(afatinib dimaleate, q.d) in Korean
      patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>All reported adverse events in patients who take at least one dose of GIOTRIF® will be noted.</measure>
    <time_frame>up to 28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Data regarding tumour assessments that are performed according to local standard of care for NSCLC may contribute to: Progression-Free Survival</measure>
    <time_frame>up to 48weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease accessment. (It is classified as Complete Response (CR), Partial Response (PR), Stable Disease (SD) or Progressive Disease (PD))</measure>
    <time_frame>up to 48weeks</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <arm_group>
    <arm_group_label>GIOTRIF</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GIOTRIF 20mg</intervention_name>
    <description>NSCLC with GIOTRIF 20mg</description>
    <arm_group_label>GIOTRIF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GIOTRIF 40mg</intervention_name>
    <description>NSCLC with GIOTRIF 40mg</description>
    <arm_group_label>GIOTRIF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GIOTRIF 30mg</intervention_name>
    <description>NSCLC with GIOTRIF 30mg</description>
    <arm_group_label>GIOTRIF</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        NSCLC in Korea
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Patients who have been started on GIOTRIF® in accordance with the approved label in
             Korea

          2. Age = 19 years at enrolment

          3. Patients who have signed on the data release consent form

        Exclusion criteria:

          1. Known hypersensitivity to afatinib or any of its excipients

          2. Patients with rare hereditary conditions of galactose intolerance, the Lapp lactase
             deficiency or glucose-galactose malabsorption

          3. Patients for whom GIOTRIF® is contraindicated according to the local label
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>110 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Boehringer Ingelheim Call Center</last_name>
    <phone>1-800-243-0127</phone>
    <email>clintriage.rdg@boehringer-ingelheim.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>one or Multiple locations</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <removed_countries>
    <country>Japan</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 6, 2017</lastchanged_date>
  <firstreceived_date>October 20, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
